Abstract
Fosamprenavir is a protease inhibitor (PI) approved for the treatment of HIV-1 infection. Fosamprenavir is a prodrug of amprenavir developed to reduce the pill burden yet maintain the unique resistance pattern and efficacy associated with amprenavir. In a head-to-head, noninferiority trial in antiretroviral treatment-naive HIV-infected patients, the antiviral efficacy and tolerability of ritonavir-boosted fosamprenavir was not inferior to ritonavir-boosted lopinavir, when the Pis were combined with two other nucleoside reverse transcriptase inhibitors. There are fewer studies published about fosamprenavir use in antiretroviral treatment-experienced HIV-infected patients. The high genetic barrier to the development of resistance to fosamprenavir and the low level of cross-resistance between ritonavir-boosted fosamprenavir and other PI regimens are notable. As with amprenavir, gastrointestinal disturbance and rash are the most frequent short-term treatment-limiting events with fosamprenavir. Treatment with ritonavir-boosted fosamprenavir can produce a durable response. To date, fosamprenavir is one of the recommended preferred PI components for the treatment of antiretroviral-naive HIV-infected patients.
Original language | English (US) |
---|---|
Pages (from-to) | 349-363 |
Number of pages | 15 |
Journal | Expert Review of Anti-Infective Therapy |
Volume | 5 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2007 |
Keywords
- Amprenavir
- Antiretroviral treatment
- Fosamprenavir
- Protease inhibitor
ASJC Scopus subject areas
- Microbiology
- Microbiology (medical)
- Virology
- Infectious Diseases